Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Zevra Therapeutics Inc ZVRA

Healthcare Biotechnology
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under... see more

Current News (NDAQ:ZVRA)

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

GlobeNewswire 5 days ago

Zevra Therapeutics, Inc. Announces CFO Transition

GlobeNewswire November 20, 2025

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

GlobeNewswire November 5, 2025

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

GlobeNewswire October 29, 2025

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

GlobeNewswire October 27, 2025

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 6, 2025

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

GlobeNewswire September 18, 2025

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

GlobeNewswire September 4, 2025

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

GlobeNewswire August 28, 2025
View More News ››

Opinion & Analysis (NDAQ:ZVRA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZVRA)

RE:Support?

Lisagerrard17 - June 6, 2022

RE:RE:RE:RE:RE:RE:RE:RE:Support?

Congrats!    What a day.   I have been buying the dips.   I will be holding this for a bit here.
mevani - March 3, 2021

RE:RE:RE:RE:RE:RE:RE:Support?

After approval with 30/13 label I can see a buyout by GPC and that could cost them $3 billion. It's not just a drug with the same...
Bobby90 - February 11, 2021

RE:RE:RE:RE:RE:RE:Support?

Sounds good......in the mean time..... I just take profits when they stare me in the face.  Good luck to you!  Cheers ...
Iseneschal - February 4, 2021

RE:RE:RE:RE:RE:Support?

If GPC buys them out then we can expect a share price of $30 minimum. New River Pharmaceuticals (Vyvanse) got bought out before approval...
Bobby90 - February 4, 2021

RE:RE:RE:RE:Support?

Still in play.......added a small position.  Cheers !
Iseneschal - February 4, 2021
View more Bullboard ››

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »